"We are pleased to be the first center in Germany to perform the Revivent TC procedure after CE mark certification," said Dr. Frerker. "The Revivent TC procedure continues to show significant clinical benefits to patients who suffer from ischemic cardiomyopathy post-myocardial infarction. It's a viable solution when guideline directed medical therapy (GDMT) is not suitable," continued Dr. Frerker.
"The 24% volume reduction should directly impact the heart's pumping efficiency, which is a positive outcome for ischemic patients. That will result in an improvement in the patient's quality of life," added Dr. Schmidt. "This is the only minimally invasive technology which enables plication of scar tissue resulting in complete exclusion outside the LV cavity," continued Dr. Schmidt.
"The Revivent TC procedure alleviates wall stress by the reshaping of the left ventricle and allowing for the heart to operate as it was intended to going forward. The immediate impact the Revivent TC procedure has on a patient is life-changing," added Dr. Bader.
About BioVentrix and the Revivent TC System
BioVentrix, a privately held medical technology company headquartered in San Ramon, Calif., is focused on developing and commercializing minimally invasive therapies for treating HF. The company recently received CE mark certification for its closed-chest Revivent TC TransCatheter Ventricular Enhancement System for plication of scar tissue in post-MI, ischemic cardiomyopathy patients. Placement of the Revivent TC System via the LIVE procedure obviates the need for more invasive surgery. Instead, small titanium anchors are placed along the outer surface of the heart and along one of the interior walls via a catheter-based approach. The anchors are then pulled towards one another, effectively excluding the scarred and non-functioning heart wall. Ventricular volume is immediately reduced as a result of the exclusion, by as much as 30-40 percent1.
Click here for corporate video with animation
Note: The Revivent TC System is approved for sale in Europe; it is not approved for sale in the United States.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioventrix-announces-the-1st-revivent-tc-transcatheter-ventricular-enhancement-procedure-in-germany-after-receiving-ce-mark-certification-300379528.html
SOURCE BioVentrix Inc.